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BACKGROUND: As HER2 is expressed in 30% of oesophageal squamous cell carcinomas (ESCCs), T-cell-based immunotherapy and
monoclonal antibodies targeted against HER2 are attractive, novel approaches for ESCCs. However, it was shown that there is an
inverse correlation between HER2 and MHC class I expression on tumours. Thus, the correlation between HER2 and MHC class I
expressions on ESCC was evaluated.
METHODS: Expressions of MHC class I and HER2 in ESCC tissues (n¼80) and cell lines were assessed by immunohistochemistry,
fluorescence in situ hybridisation (FISH), and flow cytometry. We investigated whether HER2 downregulation with small interfering
RNA (siRNA) in ESCC cell lines could upregulate the expression of MHC class I and the antigen presentation machinery
components, and could increase their sensitivity for tumour antigen-specific CTLs.
RESULTS: There was an inverse correlation between HER2 and MHC class I expressions in both tumour tissues and cell lines.
Downregulation of HER2 with siRNA resulted in the upregulation of MHC class I expression, leading to increased CTL recognition by
tumour antigen-specific CTLs.
CONCLUSION: HER2-overexpressing ESCC tumour cells showed a reduced sensitivity for CTLs through the downregulation of MHC
class I.
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The HER2/neu-proto-oncogene (HER2) is a member of the
epidermal growth-factor receptor family, and encodes a 185-kDa
transmembrane glycoprotein with tyrosine-specific kinase activity
(Coussens et al, 1985). HER2 is amplified and overexpressed in
15–20% of breast cancers (Slamon et al, 1989), and also in a
variety of other tumours such as ovarian carcinomas (Slamon et al,
1989), colorectal cancers (Al-Kuraya et al, 2007), gastric cancers,
and oesophageal squamous cell carcinomas (ESCCs) (Takehana
et al, 2002; Mimura et al, 2005). Because of its selective
overexpression in malignant tissue, HER2 has been used as a
target for immunotherapy, including humanised monoclonal
antibodies (Herceptin) and T-cell-based immunotherapy (Fisk
et al, 1995; Disis and Cheever, 1997; Baselga et al, 1998; Kono et al,
1998, 2002; Murray et al, 2000). Recent articles have shown that
collaboration between both humoural and cellular responses is
required for the complete eradication of HER2-expressing tumours
(Knutson et al, 2001; Reilly et al, 2001; Vertuani et al, 2009).
The prognosis of advanced ESCC patients remains poor despite
the use of combined modality therapy (Kato et al, 1991; Akiyama
et al, 1994; Hayashi et al, 2001; Ishikura et al, 2003). As HER2 was
reportedly expressed in 30.3% of ESCC patients (Mimura et al,
2005), T-cell-based immunotherapy and monoclonal antibodies
targeted against HER2 are therefore attractive approaches as a
novel immunoadjuvant therapy for ESCC patients.
As tumour-reactive CTLs lyse tumour cells through the
recognition of tumour antigens on MHC class I, the down-
regulation of MHC class I expression and antigen-processing
machinery (APM) components are often associated with reduced
sensitivity to lysis by CTLs (Goodenow et al, 1985; Ferrone and
Marincola, 1995; Seliger et al, 1998). Reduced MHC class I
expression on tumours is often associated with disease progression
and a poor prognosis in ovarian, colorectal, and breast cancer (Zia
et al, 2001; Watson et al, 2006; Leffers et al, 2008). Recently, we
also reported that the downregulation of MHC class I molecules is
associated with a poor prognosis in patients with ESCC (Mizukami
et al, 2008). It is noteworthy that it was shown that HER2
expression is associated with an immune escape phenotype. For
example, it was reported that there was an inverse correlation
between HER2 and MHC class I expression in murine tumour
models (Lollini et al, 1998; Herrmann et al, 2004; Kaplan et al,
2006); in addition, the inverse correlation between HER2 and TAP
expression resulted in reduced sensitivity to lysis by CTLs in
human tumours (Herrmann et al, 2004). Thus, there is a possibility
that HER2-overexpressing tumours might escape from CTLs
specific for tumour antigens, because of the downregulated MHC
class I and APM components on the tumours. However, there is
still limited information describing the relationship between HER2
and MHC class I expressions on human tumours.
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between HER2 and MHC class I expressions in ESCC; (2) the
relationship between the inhibition of HER2 signalling and
expressions of MHC class I and APM components in ESCC; and
(3) CTL function as a consequence of HER2 signal inhibition in
ESCC.
MATERIALS AND METHODS
Reagents
The following reagents were purchased from Sigma-Aldrich
(St Louis, MO, USA): Tween-20, penicillin streptomycin, human
serum albumin, and dimethyl sulfoxide (DMSO). Phycoerythrin
(PE)-conjugated mouse anti-HER2/neu antibody (Becton Dickinson,
Franklin Lakes, NJ, USA), PE-conjugated mouse IgG1 k isotype
control immunoglobulin (Becton Dickinson), PE-conjugated
mouse anti-human HLA-A2 (Becton Dickinson), PE-conjugated
mouse IgG2b k isotype control (Becton Dickinson), FITC-
conjugated mouse anti-human HLA-ABC (W6/32; eBioscience,
San Diego, CA, USA), and FITC-conjugated mouse IgG2a,
k isotype control (eBioscience) were used for flow cytometric
analysis. Rabbit anti-HER2/ErbB2 antibody (Cell Signalling
Technology, Danvers, MA, USA), rabbit anti-phosphorylated
HER2/ErbB2 (Tyr1221/1222) antibody (Cell Signalling Techno-
logy), rabbit anti-LMP2 antibody (Affinity, Mamhead, UK), rabbit
anti-LMP7 antibody (Affinity), rabbit anti-TAP1 antibody (StressGen,
Victoria, Canada), rabbit anti-Tapasin antibody (StressGen), and
rabbit anti-Actin antibody (Cell Signalling Technology) were used
as primary antibodies for western blot analysis.
Cell lines
Oesophageal squamous cell carcinoma cell lines TE-1, TE-3, and
TE-4 were a kind gift from Dr Nishihara (Institute of Development,
Aging and Cancer, University of Tohoku, Sendai, Japan). ESCC cell
lines KYSE-30 and KYSE-50 were purchased from the Health
Science Research Resources Bank (Osaka, Japan). ESTDAB049
(melanoma cell line) and HTB122 (breast cancer cell line) were a
kind gift from Dr Rolf Kiessling (Karolinska Hospital, Stockholm,
Sweden). KATO III (gastric cancer cell line) and PC-9 (lung cancer
cell line) were obtained from the IBL cell bank (Gunma, Japan).
SK-BR-3 (breast cancer cell line) and BT474 (breast cancer cell
line) were obtained from American Type Culture Collection
(Manassas, VA, USA). The TISI cell line comprises HLA-A24þ,
Tap– cells derived from a human B-lymphoblastoid cell line.
These cell lines were kept in RPMI-1640 (Invitrogen, Carlsbad, CA,
USA) with 5% FCS (Invitrogen), 50Uml
–1 penicillin, and 2mM
L-glutamine.
Patients and samples
A total of 80 consecutive patients with primary ESCCs who were
histologically diagnosed and treated in the First Department of
Surgery, University of Yamanashi Hospital, were enrolled in this
study. None of the patients had received any treatment before
surgery (preoperative radiotherapy, chemotherapy, or immuno-
therapy) and all patients had undergone oesophagectomy with
two- or three-field lymph node dissection. This study was
approved by the ethical committee of the University of Yamanashi,
and written informed consent was obtained from all individuals.
Immunohistochemical (IHC) analysis
Sections of archival, formalin-fixed, and paraffin-embedded
material, 4-mm thick, were used for IHC analysis. For HER2
staining, HercepTest (DaKoCytomation, Glostrup, Denmark) was
performed according to the manufacturer’s recommendations.
In brief, deparaffinized and rehydrated sections were incubated
with Epitope Retrieval Solution (DaKoCytomation) for 40min at
991C. The sections were washed and blocked with 3% hydrogen
peroxide for 5min. The sections were then washed and incubated
with the primary antibody, a rabbit polyclonal antibody to human
HER2, or the primary negative control antibody at room
temperature for 30min. After washing, the primary antibody was
detected using visualisation reagents for 30min of incubation at
room temperature. Subsequently, diaminobenzidine was applied as
a visualisation reagent for 10min and the section was counter-
stained with haematoxylin. Positive and negative control slides
provided with the HercepTest were used in this study. Two
observers (YM and KM) performed the IHC analysis according to
the manufacturer’s criteria, without previous knowledge of the
clinicopathological data.
For MHC class I staining, the sections were dewaxed, followed
by antigen retrieval with Epitope Retrieval Solution (Dako-
Cytomation) in an autoclave for 20min at 1211C. The sections
were blocked by Chemmate Peroxidase Blocking Solution (Dako-
Cytomation). The primary antibody EMR8-5 (Cosmo Bio Co.,
Tokyo, Japan) or the isotype control monoclonal antibody
(DakoCytomation) was applied to the sections at 41C overnight.
The sections were incubated with streptavidin–biotin complex
(Nichirei, Tokyo, Japan) for 30min, and then they were treated
with 3,30-diaminobenzidine (DakoCytomation) for 5min, and
counterstained with haematoxylin. The staining intensity was
evaluated using the following criteria: strong positive (strong), dark
brown staining in 450% of tumour cells completely obscuring the
cytoplasm; and weak positive (weak), any lesser degree of brown
staining appreciable or no appreciable staining in tumour cells.
Two observers (YM and TM) performed the IHC analysis without
previous knowledge of the clinicopathological data.
FISH analysis
Fluorescence in situ hybridisation (FISH) analysis was performed
using the PathVysion HER2 DNA Probe Kit (Abbott Molecular,
Abbott Park, IL, USA). The HER2/neu-SpectrumOrange probe is
specific for the HER2 gene locus, and the CEP 17-SpectrumGreen
probe is specific for the a-satellite DNA sequence. The FISH
procedures were performed according to the manufacturer’s
protocol. In brief, the sections were deparaffinized, dehydrated,
and incubated in 20% sodium bisulfate/2  standard saline citrate
at 431C for 20min. The sections were washed and treated with
proteinase K (Boehringer-Mannheim, Mannheim, Germany) at
371C for 25min. Subsequently, denaturation, hybridisation, and
post-hybridisation washing were performed according to the
manufacturer’s protocol. After hybridisation and post-hybridisa-
tion washing, the sections were counterstained with DAPI
(40,6-diamidine-20-phenylindole dihydrochloride). Using a fluore-
scence microscope (Olympus, Tokyo, Japan) equipped with Triple
Bandpass Filter sets (Vysis, Downers Grove, IL, USA), FISH
analysis was conducted. Signals were counted for at least 40 cancer
nuclei per tumour and analysis was performed by two observers
(KM and TM) according to the criteria provided with the
PathVysion HER2 DNA Probe Kit. A breast tumour sample, which
was previously identified as showing HER2 amplification and
overexpression, was used as a positive control for HER2 FISH.
Small interfering RNA (siRNA) transfection
The cell lines, TE1, TE3, TE4, and KYSE30, were grown in six-well
plates until they reached approximately 60% confluence, and cells
were then transfected with Opti-MEN I reduced serum medium
(Invitrogen) including 100pmol of siRNA (ERBB2 ON-TARGET-
plus SMARTpool siRNA or ON-TARGETplus siCONTROL non-
targeting siRNA; Dharmacon, Inc., Chicago, IL, USA) or without
siRNA using 5ml of Lipofectamine 2000 (Invitrogen) according to
HER2 signalling effect on MHC class I
T Maruyama et al
553
British Journal of Cancer (2010) 103(4), 552–559 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sthe manufacturer’s protocol. After 36h, cells were analysed by flow
cytometry for HER2, MHC class I, and HLA-A2 expressions. These
transfectants were always cultured in parallel for the same period
of time. Three identical but independently derived transfectants
were produced from TE1, TE3, TE4, and KYSE30 cell lines, with
each set showing comparable results.
HLA-A2402-restricted, cancer–testis antigen
(CTA)-specific CTL generation
Peripheral blood mononuclear cells (PBMCs) were collected from a
healthy HLA-A2402-positive volunteer using Ficoll Paque (GE
Health Care, Uppsala, Sweden) gradient centrifugation. Monocytes
were enriched by adherence to a plastic tissue culture flask for
90min at 371C. Adherent cells were cultured in X-Vivo (Life
Technologies Inc., Gaithersburg, MD, USA) supplemented with
1000unitsml
–1 of GM-CSF (Peprotech EC Ltd, London, UK) and
1000unitsml
–1 of IL-4 (Peprotech EC Ltd). On day 5, immature
DCs were treated with 20mgml
–1 of OK-432 (Chugai Pharmaceu-
tical Co., Tokyo, Japan) and, after 48h, these treated cells were
used as mature DCs. On day 7, mature DCs were pulsed with
20mgml
–1 of HLA-A2402-restricted URLC10 peptide (RYCN-
LEGPPI), which is immunodominant peptide derived from CTA
specific for ESCC (Suda et al, 2007), for 1h at 371C and
subsequently co-incubated with autologous PBMCs in a 1:10 ratio
in a 24-well plate. X-Vivo medium was used as the culture medium
and supplemented with 20IUml
–1interleukin-2 (IL)-2; Shionogi &
Co., Ltd, Osaka, Japan) after 2 days of culture. Cultured cells were
re-stimulated with peptide (URLC-10)-loaded, irradiated (60Gy)
autologous PBMCs on days 14 and 21. A total of 50–100IUml
–1of
IL-2 was replenished 2 days after each re-stimulation. At 1 week
after the second re-stimulation, CTLs were tested for their
antigen-specific response using the ELISpot assay based on
the combination of HLA-A2402 binding, irrelevant peptide, TTK
(SYRNEIAYL), and KOC-1 (KTVNELQNL).
Western blotting
Cell pellets were solubilised in electrophoresis sample buffer, and
sonicated for 10s, and then boiled for 10min. The protein
concentration of cell lysates was measured, and the same amount
of protein (30mg) was separated by SDS–PAGE, followed by
transfer to a polyvinylidene fluoride (PVDF) microporous
membrane (Millipore, Billerica, MA, USA) blocked in PBS (5%
milk). After blocking, the membrane was probed with primary
antibodies. The membranes were again washed and incubated with
HRP-linked goat anti-rabbit antibody (Cell Signalling Technology)
or alkaline phosphatase-conjugated swine anti-rabbit antibody
(DakoCytomation). The specific bands were visualised by ECL Plus
(Amersham Pharmacia Biotech AB, Uppsala, Sweden) or CDP-Star
substrate (Roche, Mannheim, Germany), and images were digitally
captured using a LAS1000 Lumino Image Analyser (Fuji Photo
Film, Tokyo, Japan).
ELISpot assay
The ELISpot assay was performed using a commercial kit
(Mabtech, Stockholm, Sweden), according to the manufacturer’s
protocol. In brief, 96-well plates with nitrocellulose membranes
(Millipore) were coated with a primary anti-human IFN-g capture
monoclonal antibody (1-D1K) overnight. The plates were then
treated with X-Vivo containing 1% human serum albumin for
90min. Target cells (2 10
4 per well) and CTLs (2 10
3 per well)
were co-incubated in each well with 200ml of X-Vivo for 24h.
Thereafter, a biotinylated secondary anti-human-IFN-g monoclo-
nal antibody (7-B6-1) was added for 2h and streptavidin–alkaline
phosphatase reagent was added for 1h, followed by staining with
NBT and BCIP (Invitrogen). The number of spots was quantified
using an auto-analysing system, KS ELISPOT Compact (Zeiss,
Go ¨ttingen, Germany).
IFN-c treatment of ESCC
Oesophageal squamous cell carcinomas (TE4, TE1, TE3, KYSE30,
and KYSE50) were incubated with or without IFN-g (10ngml
–1;
R&D Systems, Minneapolis, MN, USA) for 24h in X-Vivo medium.
Thereafter, MHC class I and HER-2 expressions were analysed by
flow cytometry.
Flow cytometry
Cell staining was performed according to standard flow cytometric
staining protocols, and samples were analysed using a four-colour
FACS machine (FACSCalibur, Becton Dickinson).
DNA typing of HLA in tumour cell lines
DNA typing of HLA-A gene polymorphisms was performed by the
polymerase chain reaction–sequencing-based typing (PCR-SBT)
method (Reeve and Fuller, 1995).
Statistics
The w
2 test was applied to examine the differences between
HER-2 and MHC class I expressions in ESCC. To evaluate
statistical differences between the two groups, the non-paired
Student’s t-test was used. Significance was accepted at P-values of
o0.05.
RESULTS
Expressions of HER2 and MHC class I on ESCC tissues
analysed by immunohistochemistry and FISH
A total of 80 consecutive patients with primary ESCCs were
analysed by immunohistochemistry for HER2 and MHC class I
expressions, and by FISH for HER2 gene amplification. Repre-
sentative IHC stainings of HER2 and MHC class I (EMR8-5 mAb)
on serial sections are shown in Figure 1. Although HER2-negative
case showed strong positive staining of MHC class I (Figure 1A),
strong HER2-positive (HercepTest 3þ) cases showed weak
positive staining of MHC class I (Figure 1B). Summarised data
from the 80 cases indicated that there was an inverse correlation of
HER2 gene amplification with MHC class I expression (Table 1,
P¼0.002 by w
2 analysis). These observations suggested that HER2-
positive ESCC showed downregulated MHC class I, whereas HER2-
negative ESCC showed preserved MHC class I.
HER2 and MHC class I expressions on tumour cell lines
Next, HER2 and MHC class I expressions (W6/32 mAb) were
analysed by flow cytometry using a panel of 11 tumour cell lines
including ESCC cell lines. Tumour cell lines were divided into
HER2 low- and HER2 high-expression groups according to the
levels of HER2 (Table 2). All HER2-high cell lines, TE4, SKBr3, and
BT474, showed HercepTest 3þ by immunocytochemistry and
HER2 gene amplification by FISH (data not shown). As a result,
MHC class I expression in the HER2 high-expression group was
significantly downregulated in comparison to those in the HER2
low-expression group (34.8±17.1 vs 221.4±116.6, P¼0.0175).
These results further support the inverse correlation between
HER2 and MHC class I expression.
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expression
To further evaluate the relation of HER2 expression with MHC
class I expression, we performed siRNA techniques targeting HER2
to inhibit HER2 signalling and expression. Four ESCC cell lines
(TE1, TE3, TE4, and KYSE30) were transfected with siRNA
targeting HER2 and assessed by flow cytometric analysis and
western blot.
As shown in Figure 2A and B, treatment of TE4 with HER2-
siRNA transfection resulted in the downregulation of total HER2
and phosphorylated HER2 protein in comparison to those in
control siRNA transfectants. It is noteworthy that total MHC class I
and HLA-A2 expressions in TE4-HER2-siRNA transfectants were
upregulated in comparison to those in control siRNA transfectants
(Figure 2C and D). Furthermore, even if ESCC cell lines (TE1, TE3,
and KYSE30) were HER2 low-expressing cells (FISH negative),
HER2 downregulation induced by HER2-siRNA transfection could
upregulate total MHC class I and HLA-A2 expressions (Table 3).
These observations were confirmed in four independent experi-
ments. Taken together, the downregulation of HER2 induced by
HER-2-siRNA transfection resulted in the upregulation of MHC
class I expression.
MHC class I HER2
Negative
3+ Weak
Strong
Figure 1 Representative MHC class I immunohistochemical analysis of HercepTest 0 (A) and 3þ (B) cases. The serial sections were analysed using
HercepTest and MHC class I staining. (A) MHC class I staining was strongly positive in a HercepTest 0 case. (B) MHC class I staining was weakly positive in a
HercepTest 3þ case. Original magnification  200.
Table 1 Correlation between HER2 and MHC class I in oesophageal
squamous cell carcinoma
MHC class I expression
Weak Strong
FISH positive 7 1
FISH negative 24 48
Abbreviations: FISH¼fluorescence in situ hybridisation; HER2¼human epidermal
growth factor receptor 2; MHC¼major histocompatibility complex. The w
2 test,
P¼0.002 (n¼80).
Table 2 HER2 and MHC class I expressions in tumour cell lines
HER2 (MFI) Class I (MFI)
TE4 (ESCC cell line) 687.0 43.4
SK-BR-3 (breast cancer cell line) 1570.2 49.4
BT474 (breast cancer cell line) 557.6 16.0
TE1 (ESCC cell line) 78.0 137.3
TE3 (ESCC cell line) 28.2 312.5
KYSE30 (ESCC cell line) 67.7 98.3
KYSE50 (ESCC cell line) 65.8 67.0
ESTDAB049 (melanoma cell line) 55.7 202.4
HTB122 (breast cancer cell line) 18.2 214.0
PC-9 (lung cancer cell line) 52.0 210.1
KATOIII (gastric cancer cell line) 114.8 313.8
Abbreviations: ESCC¼oesophageal squamous cell carcinoma; HER2¼human
epidermal growth factor receptor 2; MFI¼mean fluorescence intensity; MHC¼
major histocompatibility complex.
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(TE4, TE1, TE3, KYSE30, and KYSE50) is upregulated after IFN-g
treatment. As show in Figure 3, IFN-g treatment resulted in the
upregulation of MHC class I expression on all of the ESCCs tested,
whereas the HER-2 expression on ESCC did not alter after IFN-g
treatment.
Control
siCont
siHER2
Phospho-HER2
HER2
Actin
TE4 TE4
HER2
siCont siHER2
Control Control
siCont siHER2 siCont siHER2
Class I HLA-A2
200
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0
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40
0
200
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120
80
40
0
100 101 102 103 104
100 101 102 103 104 100 101 102 103 104
Figure 2 MHC class I expression after HER2 downregulation by siRNA targeting HER2. TE4 (ESCC cell line) was transfected with siRNA targeting HER2
(siHER2) or the control (siCont). (A) HER2 expression was downregulated in siHER2 transfectants, as assessed by flow cytometric analysis. (B) Total and
phosphorylated HER2 expressions were downregulated in siHER2 transfectants, as assessed by western blot. MHC class I expression (C) and HLA-A2 (D)
were increased in siHER2 transfectants, as assessed by flow cytometric analysis. The data were confirmed in four independent experiments, and
representative data are shown.
Table 3 HER2-siRNA effect on MHC class I and HLA-A2 expressions
HER2 (MFI) MHC class I (MFI) HLA-A2 (MFI)
Cell line HLA-A allele genotype siCTR siHER2 siCTR siHER2 siCTR siHER2
TE1 2402 2601 67.6 20.6 118.8 158.1 Neg Neg
TE3 0206 0206 33.3 11.7 245.8 290.3 246.7 269.7
TE4 0207 1101 605.2 304.5 40.4 73.4 33.6 76.6
KYSE30 0206 2402 78.5 26.3 115.4 165.9 93.8 148.8
Abbreviations: HER2¼human epidermal growth factor receptor 2; MFI¼mean fluorescence intensity; MHC¼major histocompatibility complex; siCTR¼control siRNA;
siHER2¼HER2 siRNA; neg¼negative.
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Figure 3 IFN-g treatment of ESCC cell lines. ESCCs (TE4, TE1, TE3, KYSE30, and KYSE50) are incubated with or without IFN-g (10ngml
–1) for 24h in
X-Vivo medium. Thereafter, MHC class I and HER-2 expressions are analysed by flow cytometry.
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URLC10-specific CTL recognition
Subsequently, we investigated whether the HLA-A2402-restricted,
tumour-specific antigen presentation on ESCC would be affected
by the alteration of HER2 expression. We generated an HLA-
A2402-restricted, URLC10-specific CTL line from a healthy
HLA-A2402-positive volunteer, in which URLC10 is an immuno-
dominant peptide derived from CTA specific for ESCC (Suda et al,
2007). The CTL line specific for URLC10 significantly recognised
TISI pulsed with URLC10 peptide, as measured using the ELISpot
assay, in comparison with TISI pulsed with irrelevant HLA-A2402
peptides (TTK and KOC-1, Figure 4A). It is noteworthy that the
recognition of HER2-siRNA-treated TE1 by URLC10-specific CTLs
was significantly enhanced in comparison to that for control
siRNA-treated TE1 (Figure 4B). These results indicate that the
downregulation of HER2 on ESCC resulted in upregulation of the
tumour antigen-specific CTL response.
Correlation of APM with HER2
We next further assessed APM components in relation to HER2
expression. ESCCs (TE1 and TE4) treated with HER2-siRNA and
control siRNA were analysed by western blotting for APM
components, including IFNg-inducible immunoproteasome subunit
low-molecular-mass polypeptide (LMP)-2, LMP-7, the transporter
associated with antigen processing (TAP)-1, and tapasin, a member
of the peptide loading complex. As a result, the expressions of
TAP-1, LMP-7, and tapasin were downregulated or lost in HER2
high-expressing TE4 in comparison to HER2 low-expressing TE1
( F i g u r e5 ) .H o w e v e r ,t h e r ew e r en o significant differences in the
expression of LMP-2, LMP-7, TAP-1, or tapasin between siHER2
and control transfectants in both cell lines (Figure 5).
DISCUSSION
This study provided novel and important findings relevant to the
relationship between HER2 and MHC class I expressions on
ESCCs. First, there was an inverse correlation between HER2 and
MHC class I expressions in both tumour tissues and cell lines.
Second, the downregulation of HER2 with siRNA transfection on
ESCC cell lines resulted in the upregulation of MHC class I
expression, leading to increased CTL recognition by tumour
antigen-specific CTLs.
HER2 was considered an attractive target for immunotherapy
because of its selective overexpression in several types of
malignant tumours, including ESCCs (Fisk et al, 1995; Disis and
Cheever, 1997; Baselga et al, 1998; Kono et al, 1998, 2002; Murray
et al, 2000). However, it was also shown that HER2 expression is
associated with an immune escape phenotype. For example, it was
reported that there was an inverse correlation between HER2 and
MHC class I expressions in murine tumour models (Lollini et al,
1998; Herrmann et al, 2004; Kaplan et al, 2006); in addition, the
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Figure 4 HER2 downregulation and CTL recognition. (A) URLC10 is an HLA-A2402-restricted peptide derived from cancer–testis antigen specific
for ESCC. The URLC10-specific CTL line was generated from an HLA-A2402 (þ) healthy donor and tested for specificity against TISI targets pulsed
with cognate peptide (URLC10) or irrelevant HLA-A2402-restricted peptides (TTK and KOC-1) using the ELISpot assay. (B) TE1 expressing URLC10 and
HLA-A2402 was treated with siRNA targeting HER2 (siHER2) or the control (siCont) and subjected to the ELISpot assay with a URLC10-specific CTL line
in combination with control tumour cell lines (PC-9 and KYSE50).
siCont
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Figure 5 The expression of antigen-processing machinery (APM)
components after HER2 downregulation. The expressions of APM
components (LMP2, LMP7, Tap1, and tapasin) were assessed by western
blot analysis against TE1 (HER2 low) and TE4 (HER2 high) transfected with
siRNA targeting HER2 (siHER2) or the control (siCont).
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a reduced sensitivity to lysis by CTLs in human tumours
(Herrmann et al, 2004). Furthermore, we previously showed that
Herceptin, which inhibits HER2 signalling and downregulates
HER2 expression on the cell surface, enhances MHC class
I-restricted antigen presentation recognised by HER2-specific
CTLs (Kono et al, 2004). Thus, there is a possibility that HER2-
overexpressing tumours might be able to escape from CTLs
specific for tumour antigens, because of the downregulated MHC
class I on the tumour. In this study, this phenomenon was further
confirmed in human ESCC, in which there was an inverse
correlation of HER2 expression with MHC class I expression.
Furthermore, the downregulation of HER2 with siRNA transfection
on ESCC cell lines resulted in the upregulation of MHC class I
expression, leading to increased CTL sensitivity.
In this study, the phenomenon that downregulation of HER2 with
siRNA transfection results in the upregulation of MHC class I
expression occurred more markedly in HER2-overexpressing than in
HER2 low-expressing ESCCs. It was also reported that the effects of
HER2 expression on MHC class I-restricted antigen presentation are
not universal among tumours with different levels of HER2 expression
(Disis et al, 2004). Thus, the reason why HER2-expressing tumours do
not always show a reduced MHC class I expression could be the
requirement for a critical ‘threshold’ of HER2 expression.
Herrmann et al (2004) showed an inverse correlation between
HER2 and TAP expressions in a human model. In the present
study, although the expressions of TAP-1, LMP-7, and tapasin were
downregulated or lost in HER2 high-expressing TE4 in comparison
to HER2 low-expressing TE1, we could not detect significant
alterations in the expressions of LMP2, LMP7, Tap1, and tapasin
between ESCC treated with HER2-siRNA and the control. This
discrepancy may be because of the limitation of the western blot
assay system to detect the difference in APM components.
Alternatively, other unknown APM components may be involved
in the downregulation of MHC class I on ESCC.
The underlying mechanisms behind the downregulation of
HER2 that could induce upregulation of MHC class I are currently
unknown. It has been shown that oncogenes, such as ras and myc,
can induce the downregulation of MHC class I surface expression,
resulting in an escape from immunosurveillance (Basolo et al,
1992; van ‘t Veer et al, 1993; La Cava et al, 1994; Griffioen et al,
1995; Cheng et al, 1996). Furthermore, it has been shown that
HER2 can activate several signal transduction pathways, including
the ras/mitogen-activated protein kinase (MAPK) and PI3K/Akt
pathways (Marmor et al, 2004). Recently, it has been shown that
HER2-inhibition resulted in the upregulation of MAPK pathway in
breast cancer cells (Lucci et al, 2010). Furthermore, Sers et al
(2009) showed that interference with MAPK activation could
upregulate HLA class I expression in colon cancer cells. These
observations strongly suggested that alteration of the signal
transduction cascades relating to HER2 may be involved in the
expression of MHC class I and APM component. Taken together,
the downregulation of HER2 with siRNA transfection on ESCC in
this study might alter the signal transduction cascade, including
MAPK or PI3K, and result in the upregulation of MHC class I
expression.
In conclusion, regardless of the underlying mechanism of the
HER2-induced downregulation of MHC class I, HER2-overexpres-
sing ESCC tumour cells showed a reduced sensitivity for tumour
antigen-specific CTLs, because of downregulation of MHC class I
on their cell surface. These results suggest the possibility that
alteration of the HER2-related signal with Herceptin, Lapatinib, or
Rapamycin may regulate MHC class I expression on ESCC cells,
leading to increased CTL sensitivity.
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